Next Article in Journal
Frontline Treatment of the Young, Fit Patient with CLL: A Canadian Perspective
Previous Article in Journal
Feasibility of Stereotactic Body Radiation Therapy on Unresectable Stage III NSCLC with Peripheral Primary Tumor: A Prospective Study (GFPC 01-14)
Article

Survival Outcomes Associated with First and Second-Line Palliative Systemic Therapies in Patients with Metastatic Bladder Cancer

1
Department of Medicine, University of British Columbia, Vancouver, BC V6T 1Z3, Canada
2
Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z3, Canada
3
Faculty of Mathetmatics and Statistics, University of the Fraser Valley, Abbotsford, BC V2S 7MH, Canada
4
Department of Medical Oncology, British Columbia Cancer, Abbotsford, BC V2S 0C2, Canada
*
Author to whom correspondence should be addressed.
Co-first authors.
Curr. Oncol. 2021, 28(5), 3812-3824; https://doi.org/10.3390/curroncol28050325
Received: 18 July 2021 / Revised: 19 September 2021 / Accepted: 23 September 2021 / Published: 29 September 2021
(This article belongs to the Section Genitourinary Oncology)
Background: Real-world data on palliative systemic therapies (PST) in treating metastatic bladder cancer (mBC) is limited. This study investigates current trends in treating mBC with first- (1L) and second-line (2L) chemotherapy (CT) and immunotherapy (IT). Methods: A chart review was conducted on patients diagnosed with stage II-IV bladder cancer in 2014–2016. Survival outcomes were compared between chemotherapy, immunotherapy, and supportive care. Results: out of 297 patients, 77% were male. 44% had stage IV disease at diagnosis. Median age at metastasis was 73 years. 40% of patients received 1L PST and 34% received 2L PST. Median overall survival (mOS) was longer in those receiving PST versus no treatment (p < 0.001). Patients receiving CT and IT sequentially had the longest mOS (18.99 months). First-line IT and CT mOS from treatment start dates were 5.03 and 9.13 months, respectively (p = 0.81). Gemcitabine with cisplatin (8.88 months) or carboplatin (9.13 months) were the most utilized 1L chemotherapy regimens (p = 0.85). 2L IT and CT mOS from treatment start dates were 6.72 and 3.78 months, respectively (p = 0.15). Conclusion: real-world mOS of >1.5 years in mBC is unprecedented and supports using multiple lines of PST. Furthermore, immunotherapy may be a comparable alternative to chemotherapy in both 1L and 2L settings. View Full-Text
Keywords: metastatic bladder cancer; chemotherapy; immunotherapy; survival; real-world data metastatic bladder cancer; chemotherapy; immunotherapy; survival; real-world data
Show Figures

Figure 1

MDPI and ACS Style

Beigi, A.; Vafaei-Nodeh, S.; Huang, L.; Sun, S.Z.; Ko, J.J. Survival Outcomes Associated with First and Second-Line Palliative Systemic Therapies in Patients with Metastatic Bladder Cancer. Curr. Oncol. 2021, 28, 3812-3824. https://doi.org/10.3390/curroncol28050325

AMA Style

Beigi A, Vafaei-Nodeh S, Huang L, Sun SZ, Ko JJ. Survival Outcomes Associated with First and Second-Line Palliative Systemic Therapies in Patients with Metastatic Bladder Cancer. Current Oncology. 2021; 28(5):3812-3824. https://doi.org/10.3390/curroncol28050325

Chicago/Turabian Style

Beigi, Arshia, Saba Vafaei-Nodeh, Longlong Huang, Shaun Z. Sun, and Jenny J. Ko 2021. "Survival Outcomes Associated with First and Second-Line Palliative Systemic Therapies in Patients with Metastatic Bladder Cancer" Current Oncology 28, no. 5: 3812-3824. https://doi.org/10.3390/curroncol28050325

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop